EP2219670A2 - Vaccin universel pour le traitement et la prophylaxie de la maladie de lyme à une usage humain et vétérinaire et son procédé de fabrication - Google Patents

Vaccin universel pour le traitement et la prophylaxie de la maladie de lyme à une usage humain et vétérinaire et son procédé de fabrication

Info

Publication number
EP2219670A2
EP2219670A2 EP08850812A EP08850812A EP2219670A2 EP 2219670 A2 EP2219670 A2 EP 2219670A2 EP 08850812 A EP08850812 A EP 08850812A EP 08850812 A EP08850812 A EP 08850812A EP 2219670 A2 EP2219670 A2 EP 2219670A2
Authority
EP
European Patent Office
Prior art keywords
borrelia
vaccine
ospa
ospc
genomospecies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP08850812A
Other languages
German (de)
English (en)
Inventor
Vladimir Vrzal
Libor Bittner
Jiri Nepereny
Josef Chumela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioveta AS
Original Assignee
Bioveta AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioveta AS filed Critical Bioveta AS
Publication of EP2219670A2 publication Critical patent/EP2219670A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Definitions

  • the whole-cell, chemically inactivated vaccine is applied with a vehicle containing polymer adjuvant substances.
  • the vaccine is applied intramuscularly, twice in the interval of two or three weeks.
  • a maintenance dose (booster) is recommended a year later.
  • the vaccination of domestic animals, especially dogs, is recommended irrespective of whether the animal was infected or the disease is just in progress.
  • the preparation of this vaccine was based on the knowledge acquired in experiments performed in rodents. The protective effect of the whole-cell vaccine was described in hamsters for the first time.
  • Example no. 1 This example of execution demonstrates the verification of protectivity of the universal vaccine after immunization of experimental cats, dogs and horses against the challenge by virulent strains of Borrelia burgdorferi sensu lato, however, it in no case limits the patent rights related to this patent.
  • the number of borrelias is determined in the dark field of microscope by means of the PETROFF HAUSSER COUNTING CHAMBER.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un vaccin universel pour le traitement et la prophylaxie de la maladie de lyme à une usage humain et vétérinaire, à base de bactérines ou de lysats ou des produits purifiés de cellules entières d'au moins une ou plusieurs espèces génomiques de Borrelia, ladite essence reposant sur le fait que chaque espèce génomique de Borrelia, choisie de préférence parmi le groupe de Borrelia burgdorferi au sens strict, de Borrelia afzelii et de Borrelia garinii, contient au moins une protéine protectrice immunogène de membrane extérieure, soit l'OspA soit l'OspC, ou simultanément les deux protéines protectrices immunogènes l'OspA et l'OspC, ou éventuellement d'autres protéines protectrices immunogènes de membrane extérieure.
EP08850812A 2007-11-14 2008-10-21 Vaccin universel pour le traitement et la prophylaxie de la maladie de lyme à une usage humain et vétérinaire et son procédé de fabrication Ceased EP2219670A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20070791A CZ301244B6 (cs) 2007-11-14 2007-11-14 Univerzální vakcína k lécbe a prevenci Lymeské borreliózy pro humánní a veterinární použití a zpusob její výroby
PCT/CZ2008/000130 WO2009062454A2 (fr) 2007-11-14 2008-10-21 Vaccin universel pour le traitement et la prophylaxie de la maladie de lyme à une usage humain et vétérinaire et son procédé de fabrication

Publications (1)

Publication Number Publication Date
EP2219670A2 true EP2219670A2 (fr) 2010-08-25

Family

ID=40600158

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08850812A Ceased EP2219670A2 (fr) 2007-11-14 2008-10-21 Vaccin universel pour le traitement et la prophylaxie de la maladie de lyme à une usage humain et vétérinaire et son procédé de fabrication

Country Status (5)

Country Link
EP (1) EP2219670A2 (fr)
CZ (1) CZ301244B6 (fr)
RU (1) RU2472525C2 (fr)
UA (1) UA102081C2 (fr)
WO (1) WO2009062454A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301244B6 (cs) * 2007-11-14 2009-12-16 Bioveta, A.S. Univerzální vakcína k lécbe a prevenci Lymeské borreliózy pro humánní a veterinární použití a zpusob její výroby
CZ301548B6 (cs) * 2008-08-20 2010-04-14 Bittner@Libor Univerzální preparát ke zvýšení obranyschopnosti, prevenci, profylaxi a lécbe Lymeské boreliózy pro humánní a veterinární použití, zpusob jeho výroby a použití
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872550B1 (en) * 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
RU2102081C1 (ru) * 1991-07-11 1998-01-20 Иммуно АГ Иммуногенная композиция против боррелиоза лайма, способ иммунизации млекопитающего против боррелиоза лайма, способ получения белка pc borrelia burgdorferi, диагностический агент для обнаружения b.burgdorferi и способ обнаружения антител к b.burgdorferi
DE69408135T2 (de) * 1993-04-29 1998-06-10 Immuno Ag Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene
US7008625B2 (en) * 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
DK0757556T3 (da) * 1994-04-11 2006-10-02 Wyeth Corp Borrelia Burgdorferi-bakterin
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
KR101192127B1 (ko) * 2006-11-03 2012-10-17 쉐링-프라우 리미티드 개 라임병 백신
CZ301244B6 (cs) * 2007-11-14 2009-12-16 Bioveta, A.S. Univerzální vakcína k lécbe a prevenci Lymeské borreliózy pro humánní a veterinární použití a zpusob její výroby

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009062454A2 *

Also Published As

Publication number Publication date
CZ301244B6 (cs) 2009-12-16
CZ2007791A3 (cs) 2009-05-27
UA102081C2 (ru) 2013-06-10
WO2009062454A2 (fr) 2009-05-22
RU2472525C2 (ru) 2013-01-20
WO2009062454A3 (fr) 2009-07-16
RU2010123897A (ru) 2011-12-20

Similar Documents

Publication Publication Date Title
US11208439B2 (en) Mutant fragments of OspA and methods and uses relating thereto
Fikrig et al. Long-term protection of mice from Lyme disease by vaccination with OspA
Potter et al. Protective capacity of the Pasteurella haemolytica transferrin-binding proteins TbpA and TbpB in cattle
JP4301415B2 (ja) ライム病組み合せ組成物とその使用
US11572392B2 (en) Mutant fragments of OspA and methods and uses relating thereto
JP2011512152A (ja) 改善された溶解度を有するＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原
Borenstein et al. Immunization of rabbits with recombinant Treponema pallidum surface antigen 4D alters the course of experimental syphilis.
Telford III et al. Efficacy of human Lyme disease vaccine formulations in a mouse model
WO2009062454A2 (fr) Vaccin universel pour le traitement et la prophylaxie de la maladie de lyme à une usage humain et vétérinaire et son procédé de fabrication
Simon et al. Lyme disease: pathogenesis and vaccine development
Donachie Vaccine development against Pasteurella haemolytica infections in sheep
US7094391B1 (en) Compositions and methods for administering Borrelia burgdorferi antigens
CZ301548B6 (cs) Univerzální preparát ke zvýšení obranyschopnosti, prevenci, profylaxi a lécbe Lymeské boreliózy pro humánní a veterinární použití, zpusob jeho výroby a použití
CZ18920U1 (cs) Univerzální preparát ke zvýšení obranyschopnosti, prevenci, profylaxi a léčbě Uymeské boreliózy pro humánní a veterinární použití
KR100258772B1 (ko) 돼지의 흉막폐염 백신 조성물
GRAVES et al. Immunization of rabbits with Spirochaeta aurantia does not induce resistance to Treponema pallidum
Ventures Patent Report
Wormser Impfstoffe gegen Lyme-Krankheit
MXPA99008146A (en) Lyme combination compositions and uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100609

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20101119

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20140922